Halozyme Therapeutics (HALO) Net Cash Flow (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Net Cash Flow data on file, last reported at $175.6 million in Q1 2026.

• On a quarterly basis, Net Cash Flow rose 190.33% year-over-year to $175.6 million in Q1 2026; TTM through Mar 2026 was $135.7 million, a 1059.57% increase from a year earlier, with the FY2025 full-year figure at $20.6 million, up 916.31% from the prior year.
• Net Cash Flow for Q1 2026 stood at $175.6 million, up from -$283.2 million in the prior quarter.
• Over the last five years, Net Cash Flow for HALO reached as high as $357.8 million in Q3 2025 and fell as low as -$283.2 million in Q4 2025.
• Historically, Net Cash Flow has averaged $11.3 million across 5 years, with a median of $23.2 million in 2024.
• Across the five-year window, Net Cash Flow plunged 15489.59% in 2023 and surged 1166.61% in 2025, its largest moves.
• Year by year, Net Cash Flow stood at $87.0 million in 2022, then slumped by 279.07% to -$155.9 million in 2023, then jumped by 75.32% to -$38.5 million in 2024, then sank by 636.31% to -$283.2 million in 2025, then jumped by 161.99% to $175.6 million in 2026.
• Per Business Quant data, the three most recent Net Cash Flow figures were $175.6 million in Q1 2026, -$283.2 million in Q4 2025, and $357.8 million in Q3 2025.